1-15 of 15
Bart Heeg
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Indirect Treatment Comparisons of Daratumumab, Pomalidomide, and Dexamethasone Versus Daratumumab, Bortezomib, and Dexamethasone or Bortezomib and Dexamethasone in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma

Jianming He, Heather Berringer, Bart Heeg, Tobias Kampfenkel, Harikumaran R. Dwarakanathan, Stephen Johnston, João Mendes, Annette Lam, Sacheeta Bathija, Eric Mackay
Journal: Blood
Blood (2021) 138 (Supplement 1): 4083.
https://doi.org/10.1182/blood-2021-146044
Published: 2021
Journal Articles

Comparison of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) with Standard of Care for Patients from Latin America with Newly Diagnosed Multiple Myeloma (NDMM) Who Were Transplant Ineligible: A Propensity Score Matching Analysis

Vania T.M. Hungria, MD PhD, Deborah M. Martinez-Banos, Maria-Victoria Mateos, Meletios A. Dimopoulos, MD, Michele Cavo, Bart Heeg, PhD, Annette Lam, Gerardo Machnicki, Jianming He, PhD, Mariana Fernandez
Journal: Blood
Blood (2019) 134 (Supplement_1): 2143.
https://doi.org/10.1182/blood-2019-123557
Published: 2019
Journal Articles

A Network Meta-Analysis (NMA) to Evaluate Comparative Effectiveness of Frontline Treatments for Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (TIE)

Thierry Facon, MD, Jesús San-Miguel, Saad Z. Usmani, MD, Meletios A. Dimopoulos, MD, Shaji K. Kumar, MD, Maria-Victoria Mateos, Michele Cavo, Bart Heeg, PhD, Sophie Van Beekhuizen, MSc, Marta Pisini, MBA, Sandhya Nair, Annette Lam, BSc, MSc, Mary Slavcev, Jianming He, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2144.
https://doi.org/10.1182/blood-2019-123561
Published: 2019
Journal Articles

Comparative Efficacy and Safety of Bortezomib, Thalidomide, and Dexamethasone (VTd) without and with Daratumumab (D-VTd) from Cassiopeia Versus Vtd from Pethema/GEM in Patients with Newly Diagnosed Multiple Myeloma Using Propensity Score Matching (PSM)

Philippe Moreau, MD, Cyrille Hulin, MD, Sonja Zweegman, MD PhD, Yannan Hu, PhD, Bart Heeg, PhD, Mahmoud Hashim, Carla de Boer, Veronique Vanquickelberghe, Tobias Kampfenkel, MD, Annette Lam, Sarah Cote, Pieter Sonneveld
Journal: Blood
Blood (2019) 134 (Supplement_1): 4740.
https://doi.org/10.1182/blood-2019-123491
Published: 2019
Journal Articles

Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)

Nikhil C. Munshi, MD, Herve Avet-Loiseau, MD PhD, Kenneth C. Anderson, MD, Paola Neri, MD PhD, Bruno Paiva, PhD, Mehmet Samur, PhD, Meletios A. Dimopoulos, MD, Margarita Kulakova, Bart Heeg, PhD, Mahmoud Hashim, Jon Ukropec, PhD, Kevin Liu, Maria Krevvata, PhD, Annette Lam, Sarah Cote, Nizar Bahlis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4742.
https://doi.org/10.1182/blood-2019-124191
Published: 2019
Journal Articles

Budget Impact of Glasdegib in Combination with Low-Dose Cytarabine for the Treatment of First-Line Acute Myeloid Leukemia in the United States

Ha Anh Pham, MSc, Sandra Milev, Shujun Li, Denise Zou, Yannan Hu, PhD, Bart Heeg, PhD, Timothy J Bell, MHA
Journal: Blood
Blood (2019) 134 (Supplement_1): 5852.
https://doi.org/10.1182/blood-2019-122709
Published: 2019
Journal Articles

Overall Survival of Glasdegib in Combination with Low-Dose Cytarabine and Azacitidine By Bone Marrow Blasts Among Adult Patients with Previously Untreated Acute Myeloid Leukemia: Comparative Effectiveness Using Indirect Treatment Comparisons

Sophie Van Beekhuizen, MSc, Timothy J Bell, MHA, Ana Gezin, MSc, Joseph C Cappelleri, PhD MPH, MS, Bart Heeg, PhD, Carl Selya-Hammer, MSc, Majed Charaan, MSc, MBA, Geoffrey Chan, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5846.
https://doi.org/10.1182/blood-2019-125852
Published: 2019
Journal Articles

Comparison of Cure Rates between Gemtuzumab Ozogamicin Plus Standard of Care Chemotherapy Vs Standard of Care Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia

Bogdan Muresan, MSc, Carla M. Mamolo, PhD, Joseph C Cappelleri, PhD MPH, MS, Ruth Mokgokong, Athina Palaka, Robert K. Hills, MA, DPhil, MSc, Nicholas Latimer, PhD, Bart Heeg, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2712.
https://doi.org/10.1182/blood-2018-99-110800
Published: 2018
Journal Articles

A Matching-Adjusted Indirect Treatment Comparison of Daratumumab-Bortezomib-Melphalan-Prednisone Versus Lenalidomide-Dexamethasone Continuous, Lenalidomide-Dexamethasone 18 Months, and Melphalan-Prednisone-Thalidomide

Meletios A Dimopoulos, MD, Michele Cavo, MD, Maria-Victoria Mateos, MD PhD, Thierry Facon, Bart Heeg, PhD, Sophie van Beekhuizen, Sandhya Nair, Marta Pisini, MBA, Annette Lam, Mary Slavcev
Journal: Blood
Blood (2018) 132 (Supplement 1): 3551.
https://doi.org/10.1182/blood-2018-99-113517
Published: 2018
Journal Articles

Impact of Modified Dose Schedule of Bortezomib, Melphalan, and Prednisone (VMP) for Previously Untreated, Transplant-Ineligible Patients with Multiple Myeloma (MM): A Matching-Adjusted Indirect Comparison

Jesus F San-Miguel, MD PhD, Maria-Victoria Mateos, MD PhD, Hartmut Goldschmidt, MD, Pieter Sonneveld, MD PhD, Meletios A Dimopoulos, MD, Bart Heeg, PhD, Mahmoud Hashim, William Deraedt, Peter Hu, Annette Lam, Jianming He, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3553.
https://doi.org/10.1182/blood-2018-99-113157
Published: 2018
Journal Articles

Treatment Regimens for Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation: A Systematic Literature Review and Network Meta-Analysis

Jesus F San-Miguel, MD PhD, Thierry Facon, Meletios A Dimopoulos, MD, Maria-Victoria Mateos, MD PhD, Michele Cavo, MD, Bart Heeg, PhD, Sophie van Beekhuizen, Marta Pisini, MBA, Sandhya Nair, Annette Lam, Mary Slavcev
Journal: Blood
Blood (2018) 132 (Supplement 1): 4741.
https://doi.org/10.1182/blood-2018-99-113668
Published: 2018
Journal Articles

An Indirect Comparison between Bosutinib, Nilotinib and Dasatinib in First-Line Chronic Phase Chronic Myeloid Leukemia

Bogdan Muresan, MSc, Carla M. Mamolo, PhD, Joseph C Cappelleri, PhD MPH, MS, Rocco J. Crescenzo, MD, Eric Leip, PhD, Andrea Viqueira, MD, Bart Heeg, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1742.
https://doi.org/10.1182/blood-2018-99-114827
Published: 2018
Journal Articles

Matching-Adjusted Indirect Treatment Comparison of Bosutinib, Dasatinib, Nilotinib and Ponatinib on Survival for Second Line Chronic Phase Chronic Myeloid Leukemia Patients

Bogdan Muresan, MS, Carla Mamolo, PhD, Joseph C. Cappelleri, PhD MPH, MS, Mark Shapiro, MD PhD, Rocco J. Crescenzo, DO, FACOI, Yun Su, MD MPH, Bart Heeg, PhD
Journal: Blood
Blood (2016) 128 (22): 3095.
https://doi.org/10.1182/blood.V128.22.3095.3095
Published: 2016
Journal Articles

Optimal Treatment Sequencing In Multiple Myeloma: An Exploratory Modeling Approach

Bart Heeg, Michel van Agthoven, Johan Liwing, Ulf-Henrik Mellqvist, Torben Plesner, Floris Logman, Verena Donatz, Johan Aschan, Hermann Einsele, Martin Kropff, Maarten Treur, Mirjam Barendse, Jean-Luc Harousseau, Antonio Palumbo, Pieter Sonneveld
Journal: Blood
Blood (2010) 116 (21): 3046.
https://doi.org/10.1182/blood.V116.21.3046.3046
Published: 2010
Journal Articles

Efficacy of Recombinant Activated Factor VII (rFVIIa) vs. Activated Prothrombin Complex Concentrate (APCC) in Patients with Hemophilia with Inhibitors: A Bayesian Meta-Analysis.

Maarten Jacob Treur, Msc, Fay McCracken, Msc, Bart Heeg, Msc, Ashish V. Joshi, PhD, MS, Stephanie Thurston, Msc, Bram Verheggen, PharmD, Botteman Marc, MSc, Frank de Charro, PhD, Ben van Hout, PhD
Journal: Blood
Blood (2007) 110 (11): 3964.
https://doi.org/10.1182/blood.V110.11.3964.3964
Published: 2007